CD4 and myeloid sarcoma: To examine the capacity of healthy donor- and patient-derived mDCs to become tolerogenic and freshly isolated HC, untreated MS and IFNb-treated MS mDCs were isolated, pre-activated with media (IL-27, lipopolysaccharide (LPS), or LPS/IL-27 for 24 h), and then co-cultured with autologous naïve CD4 T-cells.